Skip to content
10-Q

Quarterly Report

Moderna, Inc. MRNA

0001682852-26-000060

← back to feed
Filed
May 1, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 24, 2026 396.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 395M sh
Shares Diluted Q1 2026 · Mar 31, 2025 386M sh
Capex Q1 2026 · Mar 31, 2026 $62M
Capex Q1 2026 · Mar 31, 2025 $117M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$630M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.04B
Long Term Debt Q1 2026 · Mar 31, 2026 $590M
Long Term Debt Q1 2026 · Dec 31, 2025 $590M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.91B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $2.6B
Cash And Equivalents Q1 2026 · Mar 31, 2025 $1.62B
Stockholders Equity Q1 2026 · Mar 31, 2026 $7.41B
Stockholders Equity Q1 2026 · Dec 31, 2025 $8.65B
Stockholders Equity Q1 2026 · Mar 31, 2025 $10.07B
Stockholders Equity Q1 2026 · Dec 31, 2024 $10.9B
Current Liabilities Q1 2026 · Mar 31, 2026 $2.4B
Current Liabilities Q1 2026 · Dec 31, 2025 $1.99B
Total Liabilities Q1 2026 · Mar 31, 2026 $4.08B
Total Liabilities Q1 2026 · Dec 31, 2025 $3.69B
Current Assets Q1 2026 · Mar 31, 2026 $5.77B
Current Assets Q1 2026 · Dec 31, 2025 $6.54B
Total Assets Q1 2026 · Mar 31, 2026 $11.49B
Total Assets Q1 2026 · Dec 31, 2025 $12.34B
Eps Diluted Q1 2026 · Mar 31, 2026 −$3.40
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.52
Eps Basic Q1 2026 · Mar 31, 2026 −$3.40
Eps Basic Q1 2026 · Mar 31, 2025 −$2.52
Sga Expense Q1 2026 · Mar 31, 2026 $173M
Sga Expense Q1 2026 · Mar 31, 2025 $212M
Rd Expense Q1 2026 · Mar 31, 2026 $649M
Rd Expense Q1 2026 · Mar 31, 2025 $856M
Net Income Q1 2026 · Mar 31, 2026 −$1.34B
Net Income Q1 2026 · Mar 31, 2025 −$971M
Operating Income Q1 2026 · Mar 31, 2026 −$1.39B
Operating Income Q1 2026 · Mar 31, 2025 −$1.05B
Cost Of Revenue Q1 2026 · Mar 31, 2026 $955M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $90M
Revenue Q1 2026 · Mar 31, 2026 $389M
Revenue Q1 2026 · Mar 31, 2025 $108M